

A Short Review on Cardiovascular Diseases

Divya A*

Department of Pharmaceutics, Ratnam Institute of Pharmacy, Nellore, Andhra Pradesh, India

Review Article

Received: 23/09/2016
Accepted: 26/09/2016
Published: 29/09/2016

Keywords: Arrhythmia's,
Cerebrovascular disease,
Obesity, Epithelial tissue,
Rheumatic heart disease

*For Correspondence

Divya A*, Department of Pharmaceutics, Ratnam Institute of Pharmacy,
Nellore, India

E-mail:
divyapharma15@gmail.com

INTRODUCTION

Cardiovascular diseases (CVDs) include the disorders of the heart and blood vessels. It mainly involves in the narrowing or blocking of blood vessels.

List of some Cardiovascular Diseases

- i. Coronary Artery Disease
- ii. Heart Attack
- iii. Cerebrovascular Disease
- iv. Arrhythmia's
- v. Rheumatic heart disease
- vi. Congenital heart disease

The heart is like any alternative muscle in body. It requires an adequate blood to produce oxygen to permit the muscle to contract and pump. Not solely heart pump blood to the remaining parts of the body, it additionally pumps blood to itself via the coronary arteries. These arteries originate from the bottom of the artery and then broaden on the surface of the heart [1-10].

When one or a lot of coronary arteries becomes slender, it should build it tough for adequate blood to protrude in the heart, particularly throughout exercise. This may cause the carotid muscle to ache like all alternative muscle within the body. The classic symptoms of angina are chest pain or pressure and shortness of breath [11-30].

Cardiovascular diseases are still the leading cause of death worldwide. Impaired epithelial tissue operates followed by inflammation of the vessel wall results in induration of the arteries lesion formation that causes infarction and stroke. Diabetes and obesity are the main risk factors for the people living in urban areas which lead to increase in the cause of cardiovascular diseases. A major consequence for heart failure is incidence of more myocardial infarctions and infectious diseases [31-50].

CRITICAL CAUSATIVE FACTORS FOR CARDIOVASCULAR DISEASES

The most critical behavioral danger components of coronary illness and stroke are unfortunate eating regimen, physical dormancy, tobacco use and hurtful utilization of liquor. The impacts of behavioral danger variables may appear in people as raised circulatory strain, raised blood glucose, raised blood lipids, and overweight and stoutness. These "middle of the road dangers elements" can be measured in essential consideration offices and show an expanded danger of building up a heart assault, stroke, heart disappointment and different difficulties [51-70].

End of tobacco usage, diminishment of salt in the eating regimen, devouring foods grown from the ground, physical exercises and evading hurtful utilization of liquor have been appeared to lessen the danger of cardiovascular

illness. Additionally, drug treatment of polygenic disease, cardiovascular disease and high blood lipids could also be necessary to scale back vessel risk and stop heart attacks and strokes. Health policies that make tributary environments for creating healthy selections: reasonable and on the market area unit essential for motivating individuals to adopt and sustain healthy behavior [71-80].

What's a lot of, medication treatment of polygenic disorder, cardiovascular disease and high blood lipids may be necessary to diminish hazard and anticipate heart assaults and strokes. Successfulness arrangements that build favorable things for deciding on sound selections: moderate and accessible area unit crucial for propellant people to embrace and manage solid conduct [81-90].

PREVENTIVE METHODS OF CARDIOVASCULAR DISEASES

Balanced Diet

Although you may grasp that consumption sure foods will increase your cardiomyopathy risk, it's typically robust to vary your consumption habits. Whether or not you have got years of unhealthy consumption below your belt otherwise you merely wish to fine-tune your diet. Once you recognize those foods to eat additional of and that food to limit, you will be on your means toward a wholesome diet [91-95].

A balanced diet includes:

- Try to take small portions of food.
- Include fruits and vegetables in the daily menu as they were good source of vitamins and minerals.
- Take food with having low levels of saturated fatty acids.
- Reduce the salt intake and sugar content.
- Choose whole grains, a good source of fiber which helps in regulating the blood pressure levels.

Exercise Activity

Regular Exercise is great for the cardiac patients. It can strengthen the Heart activity by lowering the blood pressure.

Cardio exercise mainly Aerobics can able to lowers the blood pressure [96-100].

Other Recommendations

- Stop smoking habits.
- Avoid Alcohol intake.
- Maintain healthy weight.
- Proper medication.

REFERENCES

1. Gupta R. Burden of coronary heart disease in India. Indian Heart J. 2005;57:632-638.
2. Gupta R, et.al. Epidemiology and causation of coronary heart disease and stroke in India. Heart. 2008;94:16-26
3. Wood D. Established and emerging cardiovascular risk factors. Am Heart J. 2001;141:S49-57.
4. Shinton R and Beevers G. Meta-analysis of relation between cigarette smoking and stroke. BMJ. 1989;298:789-794.
5. Anderson KM, et.al. An updated coronary risk profile: a statement for health professionals. Circulation. 1991;83:356-362.
6. Gordon T, et.al. Death and coronary attacks in men after giving up cigarette smoking: a report from the Framingham Study. Lancet. 1974;2:1345-1348.
7. Ockene JK, et.al. The relationship of smoking cessation to coronary heart disease and lung cancer in the Multiple Risk Factor Intervention Trial (MRFIT). Am J Public Health. 1990;80:954-958.
8. Debusk RF, et.al. A case-management system for coronary risk factor modification after acute myocardial infarction. Ann Intern Med. 1994;120:721-729.
9. Jonas MA, et.al. Statement on smoking and cardiovascular disease for healthcare professionals: American Heart Association. Circulation. 1992;86:1664-1669.
10. Helgason CM and Wolf PA. American Heart Association Prevention Conference IV: Prevention and Rehabilitation of Stroke. Executive summary. Circulation. 1997;96:701-707.

11. Strong WB, et.al. Integrated cardiovascular health promotion in childhood: a statement for health professionals from the Subcommittee on Atherosclerosis and Hypertension in Childhood of the Council on Cardiovascular Disease in the Young, American Heart Association. *Circulation*. 1992;85:1638-1650.
12. Pearson TA, et.al. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary events: task force 8: organization of preventive cardiology service. *J Am Coll Cardiol*. 1996;27:1039-1047.
13. Solberg LI, et.al. The prevention-oriented practice. In: Ockene IS, Ockene JK, (eds.) *Prevention of Coronary Heart Disease*. Boston, Mass: Little Brown & Co; 1992.
14. Luria MH, et.al. Cardiovascular risk factor clustering and ratio of total cholesterol to high-density lipoprotein cholesterol in angiographically documented coronary artery disease. *Am J Cardiol*. 1991;67:31-36.
15. Messerli FH. Cardiovascular effects of obesity and hypertension. *Lancet*. 1982;1:1165-1168.
16. Reisin E, et.al. Cardiovascular changes after weight reduction in obesity hypertension. *Ann Intern Med*. 1983;98:315-319.
17. Altura BM and Altura BT. Magnesium: forgotten mineral in cardiovascular biology and angiogenesis. In *New Perspectives in Magnesium Research*. New York. 2007.
18. Khalil M and Sulaiman S. The potential role of honey and its polyphenols in preventing heart disease: a review. *Afr J Tradit Complement Altern Med*. 2010;7:315-321.
19. Gross M. Flavonoids and cardiovascular disease. *Pharmaceutical Biology*. 2004;42:21-35.
20. Little PJ. Cellular and cytokine-based inflammatory processes as novel therapeutic targets for the prevention and treatment of atherosclerosis. *Pharmacology and Therapeutics*. 2011;131:255-268.
21. Grassi D, et.al. Flavonoids: antioxidants against atherosclerosis. *Nutrients*. 2010;2:889-902.
22. Berezin AE. Biological markers of cardiovascular diseases. Part 3 Diagnostic and prognostic value of biological markers in stratification of patients with cardio metabolic risk. Lambert Academic Publishing, GmbH, Moscow;2015.
23. Kalozoumi G, et.al. MicroRNAs in heart failure: Small molecules with major impact. *Glob Cardiol Sci Pract*. 2014;2:79-102.
24. Deanfield JE, et.al. Contemporary Reviews in Cardiovascular Medicine- Endothelial Function and Dysfunction. *Circulation*. 2007;115:1285-1295.
25. Hansson GK, et al. Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med*. 2005;352:1685-1695.
26. Hadi HAR, et.al. Endothelial Dysfunction: Cardiovascular Risk Factors, Therapy, and Outcome. *Vasc Health Risk Manag*. 2005;3:183-198.
27. Erling Falk E. Pathogenesis of Atherosclerosis. *J Am Coll Cardiol*. 2006;47:c7-c12.
28. Libby P, et.al. Inflammation in Atherosclerosis: From pathophysiology to practice. *J Am Coll Cardiol*. 2009;54:2129-2138.
29. International Heart Protection Summit, September. Cardiovascular diseases in India: Challenges and way ahead. ASSOCHAM INDIA. 2011:8-30.
30. Gupta R, et.al. Correlation of regional cardiovascular disease mortality in India with lifestyle and nutritional factors. *Int J Cardiol*. 2006;108: 291-300.
31. Kim YH, et.al. Biased Agonism of G Protein-Coupled Receptors: A Potential Therapeutic Strategy of Cardiovascular Diseases. *Cardiovasc Pharm Open Access*. 2016;5:192.
32. Alam MA. Methylenetetrahydrofolate Reductase Gene Polymorphisms and Cardiovascular Diseases. *Cell Dev Biol*. 2016;5:172.
33. Altura BM, et.al. Genotoxic Effects of Magnesium Deficiency in the Cardiovascular System and their Relationships to Cardiovascular Diseases and Atherogenesis. *J Cardiovasc Dis Diagn*. 2016;S1:008.
34. Afroz R, et.al. Honey-derived Flavonoids: Natural Products for the Prevention of Atherosclerosis and Cardiovascular Diseases. *Clin Exp Pharmacol*. 2016;6:208.
35. Maksimovich IV. Transcatheter Cerebral Revascularization in the Treatment of Atherosclerotic Lesions of the Brain. *Brain Disord Ther*. 2016;5:209.
36. Mohri T, et al. Factors Affecting Recurrence of T1 and T2 Tongue Cancer Undergoing Intraoral Resection. *Otolaryngology*. 2016;6:224.
37. Berezin. Are Endothelial Cell-Derived Microparticles Predictive Biomarkers in Cardiovascular Diseases? *Atheroscler open access*. 2016;1:e101.
38. Zafar R. A New Insight into Pathogenesis of Cardiovascular Diseases: Stress Induced Lipid Mediated, Vascular Diseases. *J Cardiovasc Dis Diagn*. 2015;3:206.
39. Askari R, et.al. Quinine Syncope Diagnosed by Life Vest. *Clin Exp Pharmacol*. 2015;5:172.
40. Abd-Elbaky AE, et.al. Associations of Serum Omentin and Apelin Concentrations with Obesity, Diabetes Mellitus Type 2 and Cardiovascular Diseases in Egyptian Population. *Endocrinol Metab Syndr*. 2015;4:171.
41. Zafar R. An Insight into Pathogenesis of Cardiovascular Diseases. *J Cardiovasc Dis Diagn*. 2015;3:197.

42. Shokeen D and Aeri BT. Risk Factors Associated with the Increasing Cardiovascular Diseases Prevalence in India: A Review. *J Nutr Food Sci.* 2015;5:331.
43. Zafar F, et al. Drug Utilization Pattern in Cardiovascular Diseases: A Descriptive Study in Tertiary Care Settings in Pakistan. *J Bioequiv Availab.* 2015;7:059-062.
44. Hanefeld M, et.al. The Metabolic Syndrome and Cardiovascular Diseases: An Update of Medical Treatment. *J Metabolic Syndr.* 2014;3:160.
45. Dave MB. Pioglitazone: A Better Choice of Drug in the Pre-diabetic Patients with High Risk of Cardiovascular Diseases. *J Diabetes Metab.* 2014;5:447.
46. Skultetyova D, et al. The Impact of Blood Pressure on Carotid Artery Stiffness and Wave Intensity in Patients with Resistant Hypertension after Renal Sympathetic Denervation. *J Hypertens.* 2014;3:157.
47. Ritu M and Manika M. Blood Homocystiene and Lipoprotein (A) Levels, Stress and Faulty Diet as Major Risk Factors for Early Cardiovascular Diseases in Indians. *J Cardiovasc Dis Diagn.* 2014;2:163.
48. Han J, et.al. Stem Cell Therapy in Cardiovascular Diseases: The Reparative Mechanisms of Mesenchymal Stem Cells for Myocardial Infarction Treatment. *J Cell Sci Ther.* 2014;5: 167.
49. Patel NKJ, et al. Metabolic Syndrome and its Impact on Cardiovascular Diseases. *J Metabolic Syndr.* 2014;3:142.
50. Soejima H, et al. The Changes of Biomarkers by Telmisartan and their Significance in Cardiovascular Outcomes: Design of a Trial of Telmisartan Prevention of Cardiovascular Diseases (ATTEMPT-CVD). *J Clin Trials.* 2014;4:162.
51. Refaat B, et.al. Islamic Wet Cupping and Risk Factors of Cardiovascular Diseases: Effects on Blood Pressure, Metabolic Profile and Serum Electrolytes in Healthy Young Adult Men. *Altern Integr Med.* 2014;3:151.
52. Vasco VRL, et al. Hunting the Risk NPY and ACE Polymorphisms as Predictors of Cardiovascular Diseases: Case Report and Review of the Literature. *Intern Med.* 2014;S11:004.
53. Greco OT, et al. Cardiomyopathy and Cell Therapy: Ejection Fraction Improvement and Cardiac Muscle Mass Increasing, after a Year of Bone Marrow Stem Cells Transplantation, by Magnetic Resonance Image. *J Stem Cell Res Ther.* 2013;S6:008.
54. Charkha N, et.al. Estimating Risk of Mortality from Cardiovascular Diseases using Negative Binomial Regression. *Epidemiol.* 2013;3:127.
55. Alawieh A, et.al. Metabolomics in Cardiovascular Diseases: Biomarkers Quest. *J Data Mining Genomics Proteomics.* 2013;S2:e001.
56. Elio G, et al. LOX-1 and its Implications on Cardiovascular Diseases a Possible New Perspective Target on Atherosclerosis. *J Clin Exp Cardiol.* 2013;4:232.
57. Izumi Y. Therapeutical Potential of Microvesicles in Cardiovascular Diseases. *J Genet Syndr Gene Ther.* 2012;3:e107.
58. Nishant T, et.al. Pharmacogenomics- Personalized Treatment of Cancer, Diabetes and Cardiovascular Diseases. *J Pharmacogenomics Pharmacoproteomics.* 2011;2:107.
59. Srilatha B. High Risk Factors of Cardiovascular Diseases in Type 2 Diabetes. *J Diabetes Metab.* 2011;2:164.
60. Loh LC, et.al. Undiagnosed COPD in Patients with Established Cardiovascular Diseases: Prevalence, Symptoms Profiling and Functional Status. *J Pulmonar Respirat Med.* 2011;1:107.
61. White HS, et.al. Mechanisms of Action of Human Aldehyde Dehydrogenase Bright Cells in Therapy of Cardiovascular Diseases: Expression Analysis of Angiogenic Factors and Aldehyde Dehydrogenase Isozymes. *J Stem Cell Res Ther.* 2011;S1:001.
62. Lavoie M, et.al. Blood Glutathione Peroxidase Activity in Relation with the Risk of Cardiovascular Diseases in Obese Women. *J Diabetes Metab.* 2011;2:136.
63. Maramao F, et.al. Radiotherapy-Chemotherapy Related Heart Diseases in Surgical Setting. *J Clin Exp Cardiol.* 2016;7:444.
64. Zhou Y, et.al. Clinical Trials Using Cell-based Therapy in Ischemic Heart Diseases - A Decade's Efforts. *J Vasc Med Surg.* 2015;3:174.
65. Maduagu ATL, et.al. Prevalence of Coronary Heart Diseases Risk Factors in Adults Population Living in Nigeria's Largest Urban City. *J Nutr Disorders Ther.* 2015;5:153.
66. Kpadonou TG, et al. Preliminary Results of a Cardiac Rehabilitation Program in Patients with Compensated Heart Diseases in Sub-Saharan Africa (Benin): A Pilot Study. *Int JPhys Med Rehabil.* 2013;1:160.
67. Sauza-Sosa JC. Torsades De Pointes Induced by Levofloxacin in an Unknown Long QT Syndrome. *Cardiovasc Pharm Open Access.* 2016;5:191.
68. López MES, et al. Association of the Presence of the IS6110 Gene and the Polymorphisms of the Receptor of the Bactericide P2X₇ (A1513C and -762 C/T) in Mexican Patients with Takayasu's Arteritis and Tuberculosis. Is the Vasculitis A Manifestation of Extrapulmonary Tuberculosis?. *J Vasc.* 2016;2:109.

69. Yajun Gu, et.al. Early Subclinical Biomarkers in Onco-Cardiology to Prevent Cardiac Death. *Cardiovasc Pharm Open Access*. 2016;5:183.
70. Lamin V, et al. Endothelial Denudation of Isolated Human Internal Mammary Artery Segments. *Cardiovasc Pharm Open Access*. 2016;5:180.
71. Cen J, et.al. Study on the Features of Coronary Artery Atheromatous Plaque for Patients with Impaired Glucose Tolerance when Applying Intravascular Ultrasound. *Cardiovasc Pharm Open Access*. 2016;5:177.
72. Munesh T, et.al. Acute Cardiorespiratory Decompensation in a Child with Nephrotic syndrome with Bronchial Asthma: Is it Exaggeration of Bronchial Asthma? *Clin Pediatr*. 2016;1:104.
73. Chelo D, et.al. Challenges of Surgical Management of Childhood Cardiac Diseases in Sub-Saharan Africa, Experience of a Pediatric Cardiology Unit in Yaounde, Cameroon. *Int Ped Res*. 2016;1:103.
74. Ibraimov AI. Chromosomal Q-Heterochromatin Polymorphism in Patients with Alimentary Obesity. *Biol Med*. 2016;8:275.
75. Mustapha C. Giant Submandibular Duct Calculus: A Case Report. *Surgery Curr Res*. 2015;6:253.
76. Aronow WS. 2015 American Heart Association/American College of Cardiology/American Society of Hypertension Guidelines on Treatment of Hypertension in Patients with Coronary Artery Disease. *J Hypertens*. 2015;4:e113.
77. Sinan UY. The Cardiac Related Thrombocytopenia. *J Hematol Thrombo Dis*. 2015;3:216.
78. Hassebo MFH, et.al. Correlation between P Wave Dispersion, QRS Duration and QT Dispersion in Hospital Events in Cases of Acute Coronary Syndrome. *J en Pract*. 2015;3:196.
79. Kruk M, et al. Impact of Selection Criteria on Outcomes of Antithrombotic Trials in Acute Coronary Syndromes. *J Clin Trials*. 2015;5:220.
80. Madan T, et.al. Endovascular Intervention in Chronically Occluded Inferior Vena Cava with Modified Sharp Recanalization Technique. *J Clin Case Rep*. 2015;5:512.
81. Mahmood H, et.al. Relation of Cholesterol Level to Dietary Fat Intake in Patients of Ischemic Heart Disease. *Cardiol Pharmacol*. 2015;4:141.
82. Bolognesi M. The Importance of the Electrocardiogram (Ecg) in the Setting of Sports Pre-Participation Screening. *J Clin Case Rep*. 2014;4:e136.
83. Sadiq N. Transhepatic Approach for Device Closure of Secundum Atrial Septal Defect in Patient with Interrupted Inferior Vena Cava. *Cardiol Pharmacol*. 2014;3:120.
84. Shukla AN, et.al. The Prevalence of Hypertension: Role of Hereditary in Young and Obesity in all. *J Hypertens*. 2014;3:156.
85. Bolognesi M and Prutkin JM. Sudden Cardiac Death in a Female Triathlete: Complexities of Risk Stratification. *Intern Med*. 2014;4:161.
86. Lucas A, et.al. Women in Cardiology: The X Factor and the Heart of Medicine. *J Clin Exp Cardiol*. 2014;5:e134.
87. Gupta PN, et.al. Endomyocardial Fibrosis and the Prothrombotic State: From Hypercoagulability to Protein C Deficiency. *J Blood Disord Transfus*. 2013;5:187.
88. Kshemada K, et.al. Forensic Sciences and Growth of Cardiology. *J Forensic Res*. 2013;5:e115.
89. Brieke A, et.al. Management of Calcineurin Inhibitors-Related Chronic Kidney Disease in Cardiac Transplantation. *J Cardiovasc Dis Diagn*. 2013;1:117.
90. Kaddar N, et al. Simultaneous Determination of Dofetilide and Amlodipine in Plasma by HPLC. *J Chromatograph Separat Techniq*. 2013;4:192.
91. Ninkovic VM, et al. Predictors of In-Hospital Mortality in Patients with Acute Inferior Infarction of the Left Ventricle Accompanied by Right Ventricular Infarction when Treated with Percutaneous Coronary Intervention. *J Clin Exp Cardiol*. 2013;4:253.
92. Buttrick P. TAVR: Is The Glass Half Empty or Half Full? A Non-Interventional Cardiologist's View of a New Technology. *J Cardiovasc Dis Diagn*. 2013;1:e102.
93. Olimulder MAGM, et al. Relationship between Framingham Risk Score and Left Ventricular Remodeling after Successful Primary Percutaneous Coronary Intervention in Patients with First Myocardial Infarction and Single-Vessel Disease. *J Clin Exp Cardiol*. 2013;4:241.
94. Roberto B. Cryptogenetic Cerebral Ischemia and Spongious Atrial Septum. A New Culprit? *J Clin Case Rep*. 2012;2:233.
95. Philipp S, et al. Induction of Hypoxia Inducible Factor Rather than Modulation of Collagen Metabolism Improves Cardiac Function and Reduces Left Ventricular Hypertrophy after Aortocaval Shunt in Rats. *J Clin Exp Cardiol*. 2013;4:227.
96. de Gregorio C. Preparticipation Screening of Young Athletes: Why Still Open Questions on Performing an Electrocardiogram? *J Clin Exp Cardiol*. 2013;3:e117.
97. Philipp S, et al. The Appraisal-Trial: Evaluating RESTEN-MPTM in Patients with Bare Metal Stent De Novo Native Coronary Artery Lesions. *J Clin Exp Cardiol*. 2012;3:218.

98. Demir M and Demir C. Mean Platelet Volume is Increased in Patients with Atrial Septal Aneurysm. *J Clin Exp Cardiol.* 2012;3:200.
99. Tarcin O, et.al. Glycemic Profiles and Their Diagnostic Value among Inpatients in a Cardiology Clinic. *Endocrinol Metab Synd.* 2012;S5:005.
100. Elio G, et al. LOX-1 and its Implications on Cardiovascular Diseases a Possible New Perspective Target on Atherosclerosis. *J Clin Exp Cardiol.* 2013;4:232.